Back to Newsroom
Back to Newsroom

The Canadian Bioceutical Corporation Announces Name Change and Executive Appointment

Monday, 15 December 2014 01:42 PM

The Canadian Bioceutical Corporation

Topic:

TORONTO, ON / ACCESSWIRE / December 15, 2014 / The Canadian Bioceutical Corporation ("BCC") (TSX VENTURE: BCC.V) announces today that it has received the Final Approval of the TSX Venture Exchange to change its name from the Allegiance Equity Corporation to The Canadian Bioceutical Corporation and that the company's shares will trade on the Exchange under the symbol "BCC" effective at the opening on December 16, 2014.

"For over 20 years, our company has been involved in the development of herbal and natural-based medicines and supplements," comments Scott Boyes, BCC's new president, "and we felt that our corporate identity and branding should be more reflective of our primary business. The new name is more congruent with our strategic plan going forward and the re-branding of the company to be a more diversified life sciences company. The new name, The Canadian Bioceutical Corporation, will better reflect our business model and our projected position in the market."

Appointment of Chief Marketing Officer

BCC is also pleased to announce that its Board of Directors has approved the appointment of Michael Arnkvarn as its Chief Marketing Officer. Michael is also the Executive Vice President of CGX Life Sciences Inc. which was acquired by BCC in November and retains his position as President of two of BCC's marketing subsidiaries, The CinG-X Corporation and the CinG-X Corporation of America.

Michael Arnkvarn has an extensive management background in the operation of businesses since his graduation from McGill University in 1977 with a BSc in Agricultural Sciences. Michael a member of the Order of Agrologists and the first 18 years of his professional career were in the Ag field in both Ag finance as well as Ag business. He became a founding partner in a company which was involved in selling and installing large environmental solutions to municipalities before selling his interests in 2004 and commencing a new venture with natural ingredient health and wellness products.

Michael's skill sets include an extensive knowledge of e-Commerce and Direct Response marketing formats, both of which will be critical to the successful deployment of BCC's on-line sales and fulfillment capabilities, and the management of a field-based professional sales team.

He currently lives near Ottawa, ON with his wife and family.

About The Canadian Bioceutical Corporation

BCC, formerly Allegiance Equity Corporation, is an Ontario corporation that, for over two decades has been developing unique standardized mass-market nutraceutical products for the treatment of common ailments where present pharmaceutical treatments and Over-the-Counter (OTC) products fail to meet the needs of patients. BCC has targeted markets having clearly identified product deficiencies and dissatisfied consumers afflicted with a variety of medical conditions. BCC obtains regulatory approval and patents for these unique compounds and formulations and may produce and distribute or license its products for royalty revenues.

BCC's principal brands are CinG-X(TM) and ReliévaTM.

Cautionary Statement Regarding Forward-Looking Information

This news release includes certain "forward-looking statements" under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the Transaction and BCC's objectives and intentions. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic and social uncertainties; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; delay or failure to receive board, shareholder or regulatory approvals; those additional risks set out in BCC's public documents filed on SEDAR at www.sedar.com; and other matters discussed in this news release. Although BCC believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, BCC disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the Policies of the Exchange) accepts responsibility of the adequacy or accuracy of this release.

For further information please contact:

Scott Boyes, President and CEO
[email protected]
(416) 223-6874

 

SOURCE: The Canadian Bioceutical Corporation

Topic:
Back to newsroom
Back to Newsroom
Share by: